Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy

GlobeNewswire September 16, 2021

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine

GlobeNewswire September 14, 2021

Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder

GlobeNewswire August 23, 2021

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile August 16, 2021

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile August 13, 2021

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile August 12, 2021

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile August 11, 2021

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Axsome Stockholders and Encourages Investors to Contact the Firm

Business Wire August 10, 2021

Scott+Scott Attorneys at Law LLP Announces Investigation into Axsome Therapeutics Inc. (AXSM)

Business Wire August 10, 2021

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile August 10, 2021

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors With Losses to Contact the Firm

Business Wire August 9, 2021

AXSM INVESTOR ALERT: Rosen Law Firm Encourages Axsome Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation - AXSM

Business Wire August 9, 2021

Axsome Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire August 9, 2021

Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression

GlobeNewswire August 9, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

PR Newswire July 28, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

PR Newswire July 18, 2021

Axsome Therapeutics to Report Second Quarter 2021 Financial Results on August 9, 2021

GlobeNewswire July 15, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

PR Newswire July 14, 2021

Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia

GlobeNewswire June 15, 2021

Axsome Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 10, 2021